What is Arbutus Biopharma Corporation's D&A?

Arbutus Biopharma Corporation (ABUS) reported D&A of $11K in Q1 2026.

How has Arbutus Biopharma Corporation's D&A changed year-over-year?

Arbutus Biopharma Corporation's D&A decreased by 96.7% year-over-year, from $330K to $11K.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Arbutus Biopharma Corporation ABUS D&A

D&A at other companies

Avalo TherapeuticsAVTX

$17K-87.4%

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Arrowhead ResearchARWR

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's D&A?: Arbutus Biopharma Corporation (ABUS) reported D&A of $11K in Q1 2026.
How has Arbutus Biopharma Corporation's D&A changed year-over-year?: Arbutus Biopharma Corporation's D&A decreased by 96.7% year-over-year, from $330K to $11K.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.